




AI Enabled Drug Development Planning Session

| | |
|------------------|---|
| 8:00 - 8:40 AM | Registration & Coffee |
| 8:40 - 9:00 AM | AAIH Welcome Remarks & Workshop Framework (<i>Annastasiah Mudiwa Mhaka</i>) <ul style="list-style-type: none">• AAIH mission & purpose• Today's principles, objectives and frameworks |
| 9:00 - 10:15 AM | Primer & Context Setting: Drug Development, AI/ML and Regulatory <ul style="list-style-type: none">• AI in Health Primer - terminology and use cases (<i>Brandon Allgood</i>)• Setting common conceptual multi-stakeholder framework for the day (<i>John Baldoni</i>)• Potential application of ML in drug development and regulation (<i>Qi Liu</i>) |
| 10:15 - 10:30 AM | Coffee Break (Task-force Assignments) |
| 10:30 - 10:40 AM | Case Presentation Study #1: Scenario for Today (2019) (<i>Esther Bleicher</i>) <ul style="list-style-type: none">• Traditional diagnosis and treatment; consider <i>CVD, (lung) cancer, rare disease</i>• Patient presents with well known patient symptoms, biology and drug development path |
| 10:40 - 11:40 AM | Table Discussion with Focus on Questionnaire CPS #1 |
| 11:40 - 12:15 PM | 3 Teams Report Out |
| 12:15 - 12:30 PM | Grab Food for Working Lunch |
| 12:30 - 12:40 PM | Case Presentation Study #2: Scenario for Tomorrow (2024) (<i>Sonia De Munari</i>) <ul style="list-style-type: none">• Partially AI-enabled patient presentation and diagnosis; <i>CVD, (lung) cancer, rare disease</i>• Patient presents with unclear biology and R&D challenges |
| 12:40 - 1:40 PM | Table Discussion with Focus on Questionnaire CPS #2 |
| 1:40 - 2:20 PM | 3 Teams Report Out |
| 2:20 - 2:35 PM | Coffee Break |
| 2:35 - 2:45 PM | Case Presentation #3: Futuristic Scenario (2029) (<i>Sonia De Munari</i>) <ul style="list-style-type: none">• AI-enabled patient presentation and diagnosis; <i>App notifies patient</i> |
| 2:45 - 3:15 PM | Table Discussion with focus on Questionnaire CPS #3 |
| 3:15 - 3:35 PM | 2 Teams Report Out |
| 3:35 - 3:45 PM | Coffee Break |
| 3:45 - 4:00 PM | Moderator's Takeaways and Participating Qn List (<i>Bill Martin</i>) |
| 4:00 - 5:15 PM | Interactive Panel Discussion (<i>John Baldoni, Arnaub Chatterjee, Boris Hayete, Qi Lui</i>) |
| 5:15 - 5:30 PM | Closing Remarks and Key Next Steps |
| 5:30 - 7:30 PM | Cocktails & Networking |

AAIH TaskForce Framework: Integrated View of AI-Enabled Drug Development (IND & NDA)



Speaker Affiliations

Brandon Allgood, PhD
Chief Technology Officer,
Numerate
Vice Chairman, AAIH

John Baldoni, PhD
Chief Technology Officer,
Integral Health
Founding Chairman,
AAIH

Esther Bleicher, JD, MPH
Executive Director,
Regulatory Policy &
Counsel, Integral Health

Arnaub Chatterjee, MPA, MHA
Senior Vice President,
Product & Ecosystem,
Acorn AI - Medidata
Solutions

Boris Hayete, PhD
Senior Vice President,
Precision Medicine,
GNS Healthcare

Qi Liu, PhD, MStat, FCP
Senior Science Advisor,
Office of Clinical
Pharmacology, CDER, FDA


Sonia De Munari, PhD
Associate, Catenion

Bill Martin, PhD
President and CEO,
BlackThorn Therapeutics

Annastasiah Mudiwa Mhaka, PhD
Co-Founder and
Convenor, AAIH

Board of Directors;
Committee Co-Chair,
Federal Engagement and
Regulatory Affairs, AAIH

AAIH TaskForce Framework: *Imagining* AI-Enabled Patient-Centered, Continuous Improvement Drug Development



Illustrative